Exercise enhances the metabolic benefits of GLP-1 therapy by improving insulin sensitivity and creating additional caloric deficit
(2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism Nahra R, et al
This means people start at the lowest dose and its increased over time to keep side effects to a minimum
Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care
Naturally occurring GLP-1 cant compete with the long-lasting drugs
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test examines your genetic predispositions in GLP-1 receptor (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) pathways
